Feocromocitoma y paraganglioma (PPGL)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DIS-PHEOCHROMOCYTOMA |
|---|---|
| Tipo | Enfermedad |
| Aliaces | Tumor medular adrenalTumor de secretación de catecolaminaPPGLParagangliomaEl tratamiento con el medicamento se realizará de forma que se pueda obtener un tratamiento de la salud de los animales.Феохромоцитома та парагангліома (PPGL) |
| Situación | reviewed 2026-05-19 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 SRC-NCCN-NET-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8700/0 |
|---|---|
| icd_o_3_topography | ["C74.1"] |
| icd_10 | D35.0 |
| who_classification | WHO Endocrine and Neuroendocrine Tumours 5th ed (2022): Pheochromocytoma and extra-adrenal paragangliomas |
Notas
Pheochromocytoma is a catecholamine-secreting neuroendocrine tumor of adrenal medullary origin; extra-adrenal counterparts (paragangliomas) arise from sympathetic / parasympathetic ganglia (head/neck, thoracic, abdominal). They are biologically and clinically a single spectrum (PPGL); this entity is anchored to the adrenal subset for ICD-10 cleanliness but cross-references SDHx-driven extra-adrenal paragangliomas in prevention workstream notes. Hereditary fraction is the highest known among adult cancers (~30–40%). NCCN and Endocrine Society recommend germline panel testing (RET, VHL, SDHB/C/D/AF2, NF1, TMEM127, MAX, FH) for ALL patients with PPGL — not restricted by family history. This makes PPGL a sentinel disease for hereditary cancer surveillance pathways (RET → MEN2 prophylactic thyroidectomy; VHL → multi-organ surveillance; SDHB → lifetime PPGL + RCC surveillance). Classical clinical triad: headache + palpitations + sweating; many patients present with paroxysmal or sustained hypertension. Biochemical diagnosis: plasma free metanephrines or 24-h urinary fractionated metanephrines (preferred over catecholamines). Functional imaging (MIBG, Ga-68 DOTATATE PET) for staging and...
Utilizado por
Relevancia terapéutica
BMA-METANEPHRINES-PHEO-VHL-MEN2-SURVEILLANCE- Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and...
Algoritmos
ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMING- ALGO-MEN2-CARRIER-PROPHYLACTIC-THYROIDECTOMY-TIMINGALGO-PHEO-1L- ALGO-PHEO-1LALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE- ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE
Enfermedad
DIS-ADRENOCORTICAL-CARCINOMA- Carcinoma adrenocortical (CAC)DIS-PARAGANGLIOMA- Paraganglioma (PGL)
Indicación
IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMY- IND-PHEO-LOCALIZED-1L-ALPHA-BLOCKADE-ADRENALECTOMYIND-PHEO-METASTATIC-1L-CABOZANTINIB- IND-PHEO-METASTATIC-1L-CABOZANTINIBIND-PHEO-METASTATIC-1L-MIBG- IND-PHEO-METASTATIC-1L-MIBGIND-PHEO-METASTATIC-1L-SUNITINIB- IND-PHEO-METASTATIC-1L-SUNITINIBIND-SDH-CARRIER-INTENSIFIED- IND-SDH-CARRIER-INTENSIFIEDIND-SDH-CARRIER-SURVEILLANCE- IND-SDH-CARRIER-SURVEILLANCEIND-SDH-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-SDH-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-SDH-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-SDH-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-SDHA-CARRIER-SURVEILLANCE- IND-SDHA-CARRIER-SURVEILLANCEIND-SDHA-CARRIER-SYMPTOM-DRIVEN- IND-SDHA-CARRIER-SYMPTOM-DRIVENIND-SDHB-CARRIER-INTENSIFIED- IND-SDHB-CARRIER-INTENSIFIEDIND-SDHB-CARRIER-SURVEILLANCE- IND-SDHB-CARRIER-SURVEILLANCEIND-SDHC-CARRIER-SURVEILLANCE- IND-SDHC-CARRIER-SURVEILLANCEIND-SDHC-CARRIER-SYMPTOM-DRIVEN- IND-SDHC-CARRIER-SYMPTOM-DRIVEN
Procedimientos
PROC-NEPHRON-SPARING-PARTIAL-NEPHRECTOMY-VHL- Nefrectomía parcial ahorradora de nefrones para VHL lesión renal (≥3 cm umbral)PROC-PROPHYLACTIC-THYROIDECTOMY-MEN2- tiroidectomía profiláctica total en los portadores de mutación RET MEN2
Señal de alerta
RF-CASCADE-VHL-FDR-POSITIVE- Un pariente de primer grado del paciente (padre, hermano o hijo) tiene una posición documentada...RF-MEN2-CONFIRMED-CARRIER- Variante patógena/potible patógena confirmada en el protooncogeno RET — HOMBRE...RF-PHEO-INADEQUATE-ALPHA-BLOCKADE- El feocromocitoma / cirugía paraganglioma (adrenalectomía) está planeado o inminente SIN ...RF-SDH-CONFIRMED-CARRIER- Variante patogénica/ probable patogénica confirmada en uno de los genes SDHx — SDHB...RF-SDH-FAMILY-HISTORY-SUSPICION- Pedigree familiar sugestivo del síndrome de deficiencia de SDH (succinado desidrogenasa) - confirma...RF-SDHA-SPECIFIC-CARRIER- Variante patogénica/ probable patogénica confirmada de la línea germinal en SDHA (deshidrogenas...RF-SDHB-SPECIFIC-CARRIER- Variante patogénica/potencial patogénica confirmada en SDHB (dehidrogenas sucinatas...RF-SDHC-SPECIFIC-CARRIER- Confirmada variante patógena de la línea germinal / patógena probable en SDHC (deshidrogenas de...RF-VHL-CONFIRMED-CARRIER- El paciente tiene una variante patógena de la VHL germinal confirmada (resultado positivo de la prueba de la...
Fuentes
SRC-ENDOCRINE-SOCIETY-PPGL-2014- Feocromocitoma y Paraganglioma: Guía de Práctica Clínica de la Sociedad EndocrinaSRC-FIRSTMAPPP-BAUDIN-2024- Sunitinib para los feocromocitomas y paragangliomas progresivos metastásicos: resultados...